Renishaw诊断公司两项技术获得CE-IVD认证

  近日，Renishaw诊断公司宣布它们的RenDx多重检测系统及Fungiplex检测系统已经获得了CE-IVD认证。
  RenDx平台是一种自动化的仪器，其可以利用名为表面增强共振拉曼光谱的特殊检测技术来帮助鉴别12种念珠菌和曲霉；而Fungiplex检测系统是一种基于多重PCR的体外检测系统，其可以对血液样本中的念珠菌和曲霉的DNA进行定量检测。
  Renishaw公司总经理Rupert Jones在一份声明中表示，用于Fungiplex检测的大量的靶向目录，以及通过特殊检测技术就可以实现的高敏感性，就可以使得该项检测技术有潜力来帮助进行早期诊断，降低总体花费，并且改善真菌致死性感染患者的治疗效果。
  2013年，位于英国的Renishaw诊断公司机会已经同MRC技术公司签署了一份合作协议来开发检测感染性疾病的新型临床诊断技术。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Renishaw Dx Lands CE Mark for MDx System, Fungal Assay
Renishaw Diagnostics has announced that its RenDx Multiplex Assay System and Fungiplex assay have received CE-IVD certification.

The RenDx platform is an automated instrument that identifies 12 Candida and Aspergillus fungal species using a unique detection technology known as surface enhanced resonance Raman spectroscopy. The Fungiplex assay is a multiplex PCR-based in vitro test for the qualitative detection of Candida and Aspergillus DNA in blood samples.

"The extensive target menu for the Fungiplex assay, together with the high sensitivity that can be achieved through our exceptional detection technology, has the potential to aid earlier diagnosis, reduce overall spend, and improve patient outcomes for those susceptible to these life-threatening infections," Renishaw General Manager Rupert Jones said in a statement.

In 2013, UK-based Renishaw signed a collaborative agreement with MRC Technology to develop clinical diagnostic tests for infectious diseases.